Overview

A Study Evaluating the Efficacy and Safety of Abciximab, an Anti-platelet Therapy, in Patients Undergoing High-risk Coronary Angioplasty

Status:
Completed

Trial end date:
1992-11-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the effectiveness and safety of abciximab (an anti-platelet therapy) versus placebo in patients undergoing high risk coronary angioplasty.

Phase:

Phase 3

Details

Lead Sponsor:

Centocor, Inc.

Treatments:

Abciximab
Antibodies, Monoclonal
Immunoglobulin Fab Fragments